Inactive Instrument

Press Releases Axovant Sciences Ltd Nyse

Equities

AXON

BMG0750W1047

Press Releases

Unlock all the news: Be the first to know and act before the market!

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	02-02	GL
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	02-02	AQ
SIO GENE THERAPIES INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	06/04/23	AQ
Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	15/03/23	PU
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	15/03/23	AQ
SIO GENE THERAPIES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/02/23	AQ
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution	14/12/22	GL
Sio Gene Therapies : Announces Board Approval of Plan of Complete Liquidation and Dissolution - Form 8-K	14/12/22	PU
SIO GENE THERAPIES INC. : Other Events, Financial Statements and Exhibits (form 8-K)	14/12/22	AQ
SIO GENE THERAPIES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10/11/22	AQ
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results	10/11/22	AQ
Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	14/09/22	PU
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	14/09/22	AQ
Sio Gene Therapies : Announces Fiscal First Quarter 2022 Financial Results - Form 8-K	11/08/22	PU
SIO GENE THERAPIES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	11/08/22	AQ
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results	11/08/22	AQ
Sio Gene Therapies : Announces Fiscal Year 2021 Year-End Financial Results - Form 8-K	14/06/22	PU
SIO GENE THERAPIES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	14/06/22	AQ
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results	14/06/22	AQ
Sio Gene Therapies : Provides Corporate Update - Form 8-K	27/04/22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Axovant Sciences Ltd Nyse

Equities

AXON

BMG0750W1047

Press Releases

Filters